Suffice it to say, it has been a banner week in the world of stem cells. In this rapidly-changing market environment, it can be difficult to keep up with current events. To help you out, we’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think!
Australian stem cell company Cynata Therapeutics released news than interim analysis clearly demonstrates efficacy of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) product, CYP-001, in a preclinical model of Graft-versus-Host disease (GvHD). According to Dr. Ross Macdonald, CEO of Cynata Therapeutics, “Administration of CYP-001 appears to modulate the aggressive immune response mounted by donor cells in this GvHD proof-of-concept study. We remain on track to initiate the Phase 1 clinical trial in GvHD later this quarter.”
Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced additional positive results with the use of NiCord®, an experimental treatment for patients with high-risk blood cancers. The data demonstrates rapid engraftment, reduced bacterial infections and shortened hospitalization times. To learn more about Gamida Cell’s novel technology for functional expansion of cells, read our recent interview with Dr. Yael Margolin.
To understand the competitive nature of the iPSC research products market, it is important to consider the degree of competition that has entered the market since discovery of the cell type in 2006. There are now more than 40 companies offering iPSC research products. While most are diversified research supply companies, three companies that specialize in iPSC research products are ReproCELL, Axol Bioscience, and Cellular Dynamics International (CDI), which was acquired by FUJIFILM Holdings Corporation for $307 million in March 2015.
Pluristem Therapeutics announced that it had been granted two key cell therapy patents in Japan. The company is a clinical-stage biotechnology company that uses placental cells and a proprietary 3D technology platform to develop cell therapies. It is strengthening its IP position to support current negotiations with pharmaceutical companies in Japan regarding potential partnerships for the development and commercialization of its PLacental eXpanded (PLX) cells. To learn more, see our recent interview with Dr. Racheli Ofir.
Universal Cells Inc. is a revolutionary therapeutic genome editing company that uses nuclease-free technology to develop “off-the-shelf” stem cell products that are universally compatible. In major news, Universal Cells announced it has entered into an agreement with HEALIOS K.K. in Japan, the world’s leading company producing iPSC therapeutics. Together, Universal Cells and Healios will create Universal Donor iPSCs by editing the genes required for antigen presentation.
Recent mergers continue the trend of consolidation within the global cord blood banking market. On November 13, 2015, AlphaCord released news that it was acquiring LifeSource Cryobank. The acquisition was AlphaCord’s fifth acquisition of smaller cord blood banks. A few days ago, California Cryobank Stem Cell Services LLC, better known as “FamilyCord”, announced it has acquired Southern Cord Inc., a cord blood bank operating within the southeastern U.S. How long can the trend continue?
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and diverse market for iPSC research tools has emerged. Included below is a ten-year history of iPSC grants (source: NIH RePORTER), clinical trials (source: ClinicalTrials.gov), and scientific publications (source: PubMed.gov). Each graph suggests that the iPSC market is expanding.
This 250-page landmarket report describes the current status of mesenchymal stem cell (MSC) research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and uses of MSCs in cell therapy. It also assesses 35 leading competitors within the MSC marketplace. Claim it to acquire an understanding of market trends, efficiently target emerging opportunities, and accurately identify the current and future needs of your client base.
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.